Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.45 |
| ▸ | GRK2 | P25098 | 5/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657644 | 0.81 | NR1H2 (0.61) | LMNAMAPT | |
| SCHEMBL7200528 | 0.78 | NR1H2 (0.56) | ROCK2GRK2 | |
| SCHEMBL4873033 | 0.77 | SMN1; SMN2 (0.63) | KDM4ELMNAMAPTIDO1 | |
| SCHEMBL11589319 | 0.77 | NR1H2 (0.67) | JAK2KDM4EL3MBTL1XDHABCG2 | |
| Hydrochloric Acid SCHEMBL11589087 | 0.75 | NR1H2 (0.64) | JAK2KDM4EL3MBTL1XDHABCG2 | |
| SCHEMBL29330535 | 0.75 | HDAC3 (0.53) | JAK2KDM4EL3MBTL1ROCK2GRK2 | |
| SCHEMBL2769054 | 0.75 | JAK2 (0.49) | JAK2KDM4EL3MBTL1ROCK2GRK2 | |
| SCHEMBL4868465 | 0.73 | L3MBTL1 (0.39) | KDM4EL3MBTL1MAPT | |
| SCHEMBL2485799 | 0.73 | XDH (0.49) | KDM4EROCK2GRK2XDHLMNA | |
| SCHEMBL9253965 | 0.72 | NOTUM (0.45) | ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009087218-A1 | THIAZOLTRIAZOLES AND THIAZOLIMIDAZOLES AS ANTAGONISTS OF THE MGLUR5 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-07-16 | — | — | WO | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFB2, TGFBR1 | JAK2 1362/4885KDM4E 2127/4885L3MBTL1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.